Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Metastatic Prostate Cancer

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?

Prostate Cancer Treatment & Management: Approach Considerations, Localized Prostate Cancer, Management of Advanced and Metastatic Disease

Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer in the TRITON3 Trial – Oliver Sartor

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet

The treatment landscape of metastatic prostate cancer - ScienceDirect

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer - Gonzalez - 2021 - The Journal of Pathology: Clinical Research - Wiley Online Library

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study - European Journal of Cancer

Ipatasertib Plus Abiraterone: A New Potential Treatment for Metastatic Castration-Resistant Prostate Cancer With PTEN Loss - Cancer Therapy Advisor

Management of Metastatic Castration-Resistant Prostate Cancer in: Journal of the National Comprehensive Cancer Network Volume 19 Issue 5.5 (2021)

Prostate cancer Nature Reviews Disease Primers

Rucaparib vs. Investigator choice - Problems with TRITON-3

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial - The Lancet Oncology